HBA-JRA H.B. 1719 76(R)    BILL ANALYSIS


Office of House Bill AnalysisH.B. 1719
By: Dukes
Public Health
3/18/1999
Introduced



BACKGROUND AND PURPOSE 

Currently, gamma butyrolactone, Androstenedione, and 19-Norandrostenedione
are not classified as controlled substances and are being sold
over-the-counter as diet supplements, under the brandnames Revivarant,
Revivarant G, and Epiandostenone.  These drugs may be dangerous and
addictive. H.B. 1719 classifies gamma butyrolactone as a Schedule I
controlled substance, and classifies Androstenedione  and
19-Norandrostenedione as Schedule III controlled substances. 

RULEMAKING AUTHORITY

It is the opinion of the Office of House Bill Analysis that this bill does
not expressly delegate any additional rulemaking authority to a state
officer, department, agency, or institution. 

SECTION BY SECTION ANALYSIS

SECTION 1.  Amends Subchapter B, Chapter 481, Health and Safety Code, by
adding Section 481.037, as follows: 

Sec. 481.037.  DESIGNATION OF CERTAIN SUBSTANCES.  Provides that Schedule I
includes gamma butyrolactone and Schedule III includes Androstenedione and
19Norandrostenedione, notwithstanding any other provision of this
subchapter (Schedules) and prohibits the commissioner of public health or
the commissioner's designee from modifying Schedule I or Schedule III to
exclude these substances, notwithstanding Sections 481.032(a) (Schedules)
and 481.034 (Establishment and Modification of Schedules by Commissioner),
Health and Safety Code. 

SECTION 2.  Effective date: September 1, 1999.

SECTION 3.  Emergency clause.